Agile Therapeutics   Report issue

For profit Phase 3
Founded: Princeton New Jersey United States (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2007
NCT01250210
First Marketed Drug
2020
ethinyl estradiol (Estinyl)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

AGILE

Active Ingredients

Marketed Drugs (2)

ethinyl estradiol (Estinyl) (2020)

norgestrel (Ovral) (2020)

Drugs in Phase 3 Trials (3)

ethinyl estradiol (Estinyl) (7 trials)

norgestimate (2 trials)

norgestrel (Ovral) (8 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Vision Disorders (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 3